This study elucidates the mechanism by which SEMA4D blockade induces the formation of tertiary lymphoid structures in the neoadjuvant treatment of melanoma, providing critical experimental evidence for optimizing combination immunotherapy strategies and evaluating biomarkers.
Literature Overview
This article, titled "Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial," published in Nature Communications, systematically explores the results of a neoadjuvant clinical trial combining the SEMA4D-blocking antibody Pepinemab with PD-1 or CTLA-4 inhibitors in patients with resectable metastatic melanoma. The study focuses on evaluating the regulatory effects of this combination regimen on the phenotypic characteristics of the tumor microenvironment (TME), particularly its impact on T effector cell infiltration and the spatial distribution of immune cells.Background Knowledge
Although neoadjuvant immune checkpoint inhibitors (ICIs) have significantly improved event-free survival in melanoma patients, drug resistance and recurrence remain critical clinical challenges. Existing research indicates that the enrichment of immunosuppressive myeloid cells (such as MDSCs and tumor-associated macrophages) and impaired antigen presentation are primary mechanisms of immunotherapy resistance. SEMA4D, a glycoprotein expressed on tumor and immune cells, drives tumor migration and maintains an immunosuppressive state through interactions with Plexin B1/B2 receptors. The specific effects of interventions targeting SEMA4D in the neoadjuvant setting for melanoma remain unclear, particularly regarding whether they can synergize with PD-1 and CTLA-4 blockade to remodel TME structure and promote functional immune responses, representing an urgent scientific question to be addressed.
Research Methods and Core Experiments
This study is a pilot biomarker-driven clinical trial (NCT03769155) enrolling 38 patients with resectable metastatic melanoma. The experimental design included four treatment groups: Pepinemab combined with Nivolumab, Pepinemab combined with Ipilimumab, triple therapy with Pepinemab, Nivolumab, and Ipilimumab, and a Nivolumab monotherapy group, along with a surgery-only control group. Patients received two doses of neoadjuvant therapy followed by radical surgery, supplemented by one year of adjuvant Nivolumab treatment. The study employed multiple techniques including multiplex immunohistochemistry (mIHC), spatial transcriptomics (GeoMx), immune repertoire sequencing, and flow cytometry to deeply analyze tumor tissues and peripheral blood samples.
Key evidence showed that Pepinemab combination regimens significantly upregulated transcripts associated with activated dendritic cells (DCs) and immune recruitment pathways, and increased plasma levels of FLT3L protein. Spatial analysis confirmed increased infiltration of CD8+ T cells and CD20+ B cells within tumors in the combination therapy groups, with CD20+ B cells migrating from the tumor margin toward the tumor core. Furthermore, the formation of mature lymphoid aggregates (mLAs) was observed in the triple therapy group; these structures were rich in germinal center B cells and follicular dendritic cells and exhibited clonally expanded T cell receptor (TCR) characteristics.Key Conclusions and Perspectives
Research Significance and Prospects
These findings indicate that SEMA4D blockers can synergize with immune checkpoint inhibitors by remodeling myeloid cell function and promoting the maturation of lymphoid structures. This mechanism provides theoretical support for developing novel combination treatment regimens for melanoma and other solid tumors, particularly for overcoming immunotherapy resistance. Future research should focus on validating the clinical value of mLAs as efficacy prediction markers and exploring the potential of this strategy in combination with gene therapy or cell therapy.
Conclusion
Through a rigorous clinical trial, this study confirms the feasibility and immunomodulatory activity of neoadjuvant Pepinemab combined with PD-1 and CTLA-4 inhibitors in patients with resectable melanoma. The research not only validates the critical role of SEMA4D blockade in reversing tumor microenvironment immunosuppression and promoting the maturation of antigen-presenting cells but also reveals its unique potential in inducing the formation of mature lymphoid aggregates for the first time. The emergence of these structured immune aggregates is closely correlated with longer recurrence-free survival in patients, suggesting they may serve as novel biomarkers for evaluating immunotherapy efficacy and prognosis. From the perspective of translating laboratory findings to clinical practice, this study offers a new strategic direction for overcoming melanoma recurrence and resistance: optimizing the spatial organization of the immune microenvironment by targeting the SEMA4D-Plexin axis to enhance the durability of adaptive immune responses. This discovery not only enriches the theoretical framework of tumor immunology but also lays a solid foundation for developing more precise combination treatment regimens and improving long-term survival outcomes for patients with related diseases.
